Erschienen in:
01.11.2009 | Oncology
Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial
verfasst von:
Dow-Mu Koh, Matthew Blackledge, David J. Collins, Anwar R. Padhani, Toni Wallace, Benjamin Wilton, N. Jane Taylor, J. James Stirling, Rajesh Sinha, Pat Walicke, Martin O. Leach, Ian Judson, Paul Nathan
Erschienen in:
European Radiology
|
Ausgabe 11/2009
Einloggen, um Zugang zu erhalten
Abstract
The purpose was to determine the reproducibility of apparent diffusion coefficient (ADC) measurements in a two-centre phase I clinical trial; and to track ADC changes in response to the sequential administration of the vascular disrupting agent, combretastatin A4 phosphate (CA4P), and the anti-angiogenic drug, bevacizumab. Sixteen patients with solid tumours received CA4P and bevacizumab treatment. Echo-planar diffusion-weighted MRI was performed using six b values (b = 0–750 s/mm2) before (×2), and at 3 and 72 h after a first dose of CA4P. Bevacizumab was given 4 h after a second dose of CA4P, and imaging performed 3 h post CA4P and 72 h after bevacizumab treatment. The coefficient of repeatability (r) of ADC total (all b values), ADC high (b = 100–750) and ADC low (b = 0–100) was calculated by Bland–Altman analysis. The ADC total and ADC high showed good measurement reproducibility (r% = 13.3, 14.1). There was poor reproducibility of the perfusion-sensitive ADC low (r% = 62.5). Significant increases in the median ADC total and ADC high occurred at 3 h after the second dose of CA4P (p < 0.05). ADC measurements were highly reproducible in a two-centre clinical trial setting and appear promising for evaluating the effects of drugs that target tumour vasculature.